Almost the whole of my immunological thinking has been concerned with a phenomenon first clearly recognized by Ehrlich and for which his phrase, 'horror autotoxicus', has survived. This is simply that neither in man nor experimental animal will body components provoke antibody production or any other recognizable immunological reaction, although many of these components can readily be shown to be highly antigenic in other individuals or species. One might in fact define immunological phenomena as reactions which are based on the capacity of the vertebrate to recognize and react against chemical configurations foreign to the body or at least to its less specialized tissues. To me the first requirement of immunological theory is that it should account for the capacity of an organism to distinguish between self and not-self. An understanding of this capacity is not a purely theoretical luxury. During the last decade it has become of high importance in practical medicine and surgery. On the one hand we have the requirements which must be fulfilled if blood transfusion is to be safe or if organ transplantation is to be feasible as a therapeutic manipulation. On the other we have the troubles that beset the patient with autoimmune disease when for one cause or another the imperative against immunological attack on normal body components has been abrogated.
Immunopathology is a very recent development and there is much controversy about the basic nature of autoimmune disease and about the criteria necessary to establish a clinical condition as of autoimmune nature. In an attempt to provide a simple classification of the human con-ditions which either have been or may eventually be shown to have an autoimmune wtiology, Table 1 may be considered. In Group I we have conditions which appear to result from immunological attack on constituents which are specific for a single organ or group of organs and which appear to be directed against antigenic determinants which rarely come into the extracellular environment, including in this the blood and lymph circulations. Hashimoto's disease of the thyroid is by far the best studied of these conditions and the list shown may well be both incomplete and inaccurate. The diseases enumerated in this and the other three groups are arranged as it were in descending order of confidence. We are almost completely ignorant of the aetiology of multiple sclerosis; it is no more than a guess that it represents an autoimmune disease. 
Hypergammaglobulinsemia
Group II contains the classical autoimmune diseases where the attack is on common widely distributed components of the tissues. In systemic lupus erythematosus (SLE), we know there are antibodies in the blood against a group of substances found in cell nuclei, nucleic acid, nucleoprotein and histone, for example. The fact that DNA (deoxyribonucleic acid) from virus, bacterium or mammal, will react equally well with the antibody in most SLE serums is, I believe, one of the most revealing facts in this field. Lymphocytes are liable to be broken down rapidly under a variety of 'stress' situations. This is specially evident in thymus and lymph nodes and we can be sure that at all times there are nuclear components including DNA in the environments where immunological processes are initiated and implemented. Of all the self components which must not stimulate immunological activity, DNA should be the most sacrosanct. Yet under the conditions existing in SLE, antibodies appear which, because they react with any form of DNA, must be active against the individual's own DNA as well. The implication is clear that antibody can be made against many self components, perhaps against every macromolecular species in the body, but that a positive homeostatic control prevents the emergence into activity of cells capable of making such antibody.
Similarly in acquired haemolytic anvmia we have antibody against patterns on the red cell surface that are common to the majority of human beings. In rheumatoid arthritis the characteristic antibody reacts against circulating gamma globulin, particularly when it is in the denatured form. Both statements need qualification in detail but all that is needed here is to emphasize the accessible nature of the body components against which immunological activity is directed.
Groups I and II are characteristically severe and often progressive and fatal diseases. In Group III I have placed a few conditions which have many of the marks of autoimmune disease which are apparently initiated by the occurrence of some bacterial (usually streptococcal) or viral infection and undergo more or less rapid remission when the infection is eliminated.
Finally, in Group IV we have conditions on the borderline between autoimmune disease and neoplasia.
For the rest of this lecture I shall neglect completely Groups III and IV and as examples I shall make use chiefly of Hashimoto's thyroiditis from Group I and of SLE as the most lethal and illuminating of the diseases in Group II.
There is no question that prevention and treatment of autoimmune conditions provide some of the most important unsolved problems in medicine. If those of us in the laboratories are to make an effective contribution to these problems, we obviously need a valid experimental model and my primary concern here is to discuss how far the strain of mice we call NZB/B1 provides such a model. The first requirement, then, is to consider the general characteristics of human autoimmune disease which we should hope to imitate in our model:
(1) Conditions like Hashimoto's disease or SLE arise spontaneously without any clear indication of an initiating environmental cause. The thyroid condition characteristically arises in women after middle age, usually in quite insidious fashion. SLE is usually first recognized in adolescence or young adult life and often may appear to have been initiated by some episode like a mild infection or a penicillin reaction. Sometimes these may act as triggers to set the clinical process in action but probably they are more often early manifestations of the disease or mere coincidences.
(2) A constitutional background of some sort is obviously involved and there is much evidence accumulating that both our examples have a significant familial incidence and that genetic factors are of major importance. In virtually all the accepted autoimmune diseases, females are more frequently affected than males, the only exception being polyarteritis nodosa.
(3) Both SLE and Hashimoto's disease are progressive in character. When untreated or given only symptomatic treatment, SLE usually terminates fatally after a few years from impairment of kidney function, Hashimoto's disease tends to progress till thyroid function is burnt out. A high proportion of cases of myxcedema are probably end-results of the disease.
(4) With increasing interest in autoimmune disease and more careful examination, it is becoming clear that many patients show symptoms or signs of some other autoimmune condition than that of his or her primary diagnosis. SLE is characteristically protean in its manifestations and it is a classic difficulty to be unable to decide whether chronic active hepatitis, or rheumatoid arthritis, should be called atypical SLE if LE cells are regularly or occasionally demonstrated. Such multiplicity is not necessarily confined within one of our groups. There is a much higher incidence of rheumatoid arthritis amongst patients with myasthenia gravis than in a normal population of similar age and sex. Hashimoto's disease may be associated with SLE, rheumatoid arthritis and chronic hepatitis, while several examples of macroglobulinmmia have been described which had rheumatoid factor in the serum.
Experimental Models of Autoimmune Disease
Until the work on NZB/Bl mice developed, all experimental work on autoimmune disease was perforce carried out with genetically normal animals treated in some way that would inflict immunological damage on their cells. None of these models fulfils all the requirements, but they do throw a great deal of light on the various ways in which tissue damage can be produced by antibodies or immunologically competent cells. We can summarize the situation briefly by saying that immunological damage to cells and tissues of a normal animal can be produced in three principal ways:
(1) In the first method cells from animals of the species to be tested as recipients are used to immunize animals of another species. Antiserum so obtained is tested for its power to produce demonstrable damage in animals of the recipient species after appropriate administration.
(2) In this approach conditions are arranged to allow permanent implanting of adult lymphoid cells into an individual of the same species but of different genotype. Splenic cells from a suitable donor strain may be able to multiply in and produce damage in a recipient of different genotype (a) if the cells are injected before birth or very soon afterwards, (b) if the recipient is rendered immunologically nonresponsive by appropriate X-irradiation, (c) if the recipient is an A x B F1 which will accept A cells but which owing to the presence of antigens characteristic of B is foreign to A and therefore liable to immunological attack by competent A cells.
(3) The third method is to immunize the recipient with emulsions prepared from appropriate organs from animals of its own genotype provided (a) the emulsion is injected along with Freund's adjuvant (water in oil emulsion plus killed mycobacteria) and (b) the organ is one containing an inaccessible antigen.
It will be convenient to discuss only one example from each of these categories out of the plethora of available reports.
(1) The classical example of the production of lesions by antiserum produced in a different species is Masugi nephritis (1933) . Rabbits are treated by injection of suspensions or extracts of rat kidney cells and when an adequate concentration of antibody is present the serum is collected.
Intravenous injection of this serum into rats produces a severe or fatal glomerulonephritis not unlike the acute human disease. It is still a matter of controversy how the kidney damage is produced. Perhaps the nearest we can come is to say that when an immunological reaction involves the surface of a cell it induces with variable intensity an increase in the permeability of that surface with release of intracellular contents and a variety of subsequent changes. The fact that antigenantibody complexes produced either in vitro or in vivo are toxic and, in particular, if given intravenously can produce severe kidney damage, may eventually prove to be a key to the general understanding of immunological damage.
(2) Perhaps the most straightforward example is the disease produced in young adult F1 hybrid mice by injection of lymphoid cells from one of the parent strains and particularly with cells of a mouse which has been immunized either with F1 cells or with cells from the other parent strain.
The intensity of the disease produced varies according to the strains used. With some combinations cells from the untreated parent will be lethal to all the injected F1 individuals. For other combinations active immunization of the donor is required. The disease shows a wide range of effects. There is a characteristic atrophy of lymphoid tissue; hxmolytic anmmia often develops and skin and kidney lesions are common. The point to be emphasized from the work of Oliner et al. (1961) is that the lesions result from the implantation and proliferation of immunologically competent cells closely related genetically to those of the host but recognizing one or more host antigens as foreign.
(3) The first example of immunological damage produced by injection of an antigen corresponding to that in the damaged organ was probably the rare paralytic sequele of Pasteurian treatment for rabies. An experimental model was provided by Rivers & Schwentker in 1935 and more recently the use of Freund's adjuvant has made experimental allergic encephalomyelitis easy to produce in a variety of laboratory animals. There are several points of interest in this condition: (a) It is almost impossible to produce without the use of Freund's adjuvant. (b) Once animals have recovered they are immune to the effect of a second attempt. (c) Transfer to other individuals is possible by cells but not by serum. (d) Circulating antibody has a protective effect.
As with similar experimental production of thyroiditis the condition is not a progressive one.
Experimental work along these lines has pro-vided many stimulating ideas for the further study of the human conditions in which we are primarily interested but none of the three approaches allows any direct study of the important characteristics of the human diseases which I enumerated earlier.
The Mouse Strain NZB/Bl I should now like to turn to the main topic of this lecture, the use of a strain of mice spontaneously subject to autoimmune disease as an experimental model of the human conditions. I was first told of these mice by Sir Charles Hercus who showed me a brief account of their characteristics by Bielschowsky et al. (1959) . The essential finding was that most mice of this strain developed signs of an autoimmune type hvmolytic anmmia between 5 and 8 months of age. The strain in question had been developed by Dr Marianne Bielschowsky in Dunedin by brother-sister mating from an outbred domestic stock and now appears to be essentially homozygous. Dr Bielschowsky kindly gave us a breeding nucleus which has been steadily built up over the last two and a half years and is now providing a substantial amount of information, some of which has been published by Dr Margaret Holmes and her colleagues (1961) .
Throughout the work the chief index we have used has been the direct Coombs (D.C.) test. This is done by using an antimouse gamma globulin serum prepared in rabbits and absorbed free of any mouse red cell agglutinins with washed red cells from mice of standard strains. Blood samples in citrate from NZB/B1 mice were washed twice with warm saline and tested for agglutination by the antiglobulin serum diluted 1: 5 and 1: 50 with a saline control for spontaneous agglutination.
In the future much more emphasis may be placed on the presence of circulating antibody of incomplete type which is found in most or all of the mice showing a D.C. positive test. This is tested for by the use of papain-treated red cells. Irrespective of whether such cells are from young NZB/BI mice or from any of the standard strains of mice which we have available for test, they are equally agglutinated by the serum of NZB/Bl mice over 7 months old and not by that ofyounger mice or of standard strains. There is a wide range of titres amongst older mice, the significance of which is yet to be assessed.
In Fig 1 are shown the cumulative percentages of positive D.C. tests from three groups of mice to show development of the hemolytic anemia.
The first line is concerned with mice of the standard NZB/Bl strain, the second with the F1 generation of NZB/Bl x C3H hybrids and the third with the back-cross F1 x NZB/Bl. In the standard line there is a sharp rise from nil to about 90 % over the period from 5 to 8 months of age, with a small continuing proportion of conversions thereafter. We have seen only two reversions from positive D.C. to negative; both showed hyperplasia or neoplasia of lymphoid elements in the spleen. F1 mice followed to the age of 9 months have so far shown no positive D.C. but Dr Bielschowsky has told us in a personal communication that F1 animals, from a cross with another line NZB/C not showing autoimmune manifestations which was derived from the same outbred stock, show a proportion of positive D.C. in old mice.
Our F1 C3H x NZB/Bl were back-crossed to NZB/Bl and the offspring have been followed now for eight months. Nearly 40% have given a positive Coombs test. It appears therefore that in relation to C3H we are dealing with a single autosomal recessive gene. This may be of importance when we come to interpret the meaning of the multiple manifestations of autoimmune disease which are shown by these mice. I will pass over very briefly the findings already published that the D.C.-positive state can be transferred to young mice of NZB/B1 strain by inoculation of 20 x 108 nucleated spleen cells from a mouse over 8 months of age showing a positive test. This has been published (Holmes et al. 1961) and gives direct evidence of the existence in affected mice of abnormal cells. An interesting additional point may be mentioned that a similar number of cells from lymph nodes will not transfer the condition. If, however, a splenectomized NZB/B1 mouse is left for several months, abdominal lymph nodes become red and on section show the presence of haematopoietic tissue. Cell suspensions from these lymph nodes have given positive transfers.
Pathological findings in these mice, apart from the positive D.C. test, have been interesting and diverse. In this section we are concerned with those mice which were allowed to age without significant experimental treatment, apart from routine blood studies and, in the case of a substantial proportion of males, castration, and examined as soon as possible after natural death or, as was usually the case, when they appeared moribund and were killed. In old mice enlarged spleen and granular yellowish kidneys were the commonest macroscopic findings at autopsy; occasional evidence of liver damage and an abnormal incidence of gall-stones were also noted.
In most cases the splenic enlargement was due to the large proportion of hematopoietic tissue, with giant cells (megakaryocytes ?) a prominent feature. The trabeculie and white pulp showed a variety of appearances and in about 20% of old mice there was extensive hyperplasia of reticulum or lymphoid cells, in some instances frankly malignant in character. Typical thymoma with lymphatic leukaemia was rare but no attempt was made to assess the malignancy of these conditions by transplantation.
The kidneys very frequently showed a gross chronic nephritis with hyaline change in the glomeruli which we have interpreted as amyloid in character. Heavy periarterial accumulations of lymphocytes with infiltration of lymphocytes and plasma cells between the tubules were present in almost all old mice of this strain. Tubular damage ran approximately parallel to the extent of the glomerular changes. Tissue Accumulations of Lymphocytes andPlasma Cells I have mentioned that plasma cell infiltration was common in affected kidneys. This had a characteristic peripheral relation to the perivascular accumulations of lymphocytes and set a pattern for similar findings in a number of other organs. The lungs often showed small macroscopic opacities which on section proved to be accumulations of lymphoid cells in relation to bronchioles or large blood vessels. Within these accumulations one frequently saw rounded areas of packed lymphocytes, often including a number of cells in mitosis, which closely approached the appearance of a germinal centre. As one moved peripherally from such centres the proportion of plasma cells showed an irregularly progressive increase. Amongst these it was also fairly common to find a pyroninophil cell undergoing mitosis.
Essentially similar findings have been obtained for the liver and in one instance the wall of the urinary bladder. A specimen of special interest came from muscle infested with Sarcocystis muris. This is a protozoal disease of mice which we have encountered on three occasions only in several hundred autopsies on NZB/Bl mice. Only single sections from a piece of affected muscle were examined and the results might not necessarily have been representative of the conditions in other muscles. With this reservation, one mouse showed the typical cysts and the equally typical complete absence of inflammatory cellular reaction. The next one was approximately equally heavily infected but here there was an extremely active cellular response. In the section there is a well-marked germinal centre with lymphocytes and plasma cells at its edge and apparently spreading out from here massive accumulations of typical plasma cells. The distribution of plasma cells and the damaged appearance of muscle fibres adjacent to the main accumulations strongly suggested that the immunologically active cells were reacting to an antigen derived from the muscle rather than one from the protozoal cysts.
We have had no opportunity yet to investigate the nature of the antibody in these plasma cells by Coon's immunofluorescent techniques but there should be no insuperable difficulty in eventually identifying the antigens toward which they are directed. For the present we may venture the hypothesis that the germinal centres and plasma cells seen in the lesions we have been discussing are immunologically competent cells reactive against one or more of the 'self' antigens present in the tissue concerned. This at least will provide a guide to the sort of experiments that are needed to test the hypothesis.
The Thymic Lesions in NZB/BI Mice
There is great current interest in the thymus as a probable site for the proliferation and differentiation of those cells whose descendants will be concerned with the phenomena of homograft rejection and similar processes (Miller 1961 , Burnet 1962 , Miller et al. 1962 . Further, it has been known for many years that of thymuses removed surgically from patients with myasthenia gravis about 70 % show numerous germinal centres and lymph follicles in the medullaappearances never seen in normal thymuses. The growing evidence that myasthenia gravis is an autoimmune disease stimulated us to look for similar lesions in the thymus of NZB/Bl mice. The fact that they are present in a high proportion of mice over 7 months of age, and are not seen in old mice of other breeds, has seemed to us to add even further significance to the thymus as an immunological organ.
It is well known that the thymus diminishes in size with age and is particularly prone to undergo severe atrophy when exposed to stress such as infection, exposure to X-irradiation, or administration of steroid drugs. The thymus from mice killed when moribund from age or infection is very small, lacks cortex completely and shows a disorganized medulla. Useful histological information can therefore only be obtained from mice killed while still apparently healthy.
We are still in the process of collecting quantitative information about the thymic appearances and for the present I can only state that in animals over 7 months of age and showing no gross atrophy of the thymic cortex, about 80% show the lesions described below.
In young mice the thymus is largely composed of cortex, the medulla appearing in an average section as a group of unconnected paler staining areas, in all occupying no more than one-fifth to one-tenth the area of the cortex. The ratio probably changes slowly in favour of the medulla as the animal ages. The characteristic abnormality in older NZB/Bl mice is seen as an enlargement of an area of medulla as a result of proliferation of lymphocytic cells in a fashion quite distinct from what is seen in the normal cortex. There is very little evidence of any lymphocytic proliferation in the medulla of other strains of mice.
In the fully developed condition, examination of sections through the whole of a lobe has shown the existence of a complex of lymph follicles and germinal centres in different degrees of development. The following features, not all of which will necessarily be seen in a single section, may be mentioned. In the germinal centre mitoses are to be seen and many of the cells in sections stained with Unna-Pappenheim show a thin rim of pyroninophil cytoplasm; pyknotic nuclei and nuclear fragments usually in macrophages are common. In some instances a well-defined zone of small lymphocytes completely surrounds a germinal centre, more commonly there are one or two crescentic areas or there may be no accumu-lation at all. In other sections the lymph follicle may appear simply as a round or oval mass of small lymphocytes in the medulla.
Mast cells are conspicuous in most welldeveloped complexes, lying characteristically at the periphery of the medullary lymph follicles.
They are much more frequent than in any thymic sections from other strains of mice which we have examined. Their origin and significance is obscure but their clear relation to the medullary complex has led to our working assumption that the presence of considerable numbers of mast cells in an atrophied thymus indicates past activity. Plasma cells are seen only very rarely in normal thymuses but are common in the neighbourhood of the proliferative complexes in old NZB/BI mice. Another striking feature absent from normal thymuses is the presence of intrathymic lymphatics closely packed with small lymphocytes. As might be expected from a process by which germinal centres arise and subsequently lose their activity while new centres appear in the vicinity, a great variety of appearances may be met with and in addition to the features already mentioned there are sometimes accumulations of cells with extensive lightly pyroninophil cytoplasm closely resembling the litoral cells of lymph node sinuses.
Increasing experience of sections from moribund mice with atrophic thymuses suggests that it is possible to recognize the signs of 'burnt out' processes of lymphocytic proliferation in the medulla. It is still too early, however, to attempt a comprehensive account of the sequence ofchanges in the thymus with age. At the present time we are specially interested in the relationship between thymic appearances, incomplete antibody and splenic changes in the period between 100 and 250 days of age in an attempt to elucidate the sequence of processes at the initiation of the auto- Signs of disease arise spontaneously and in this homozygous stock at a fairly regular age. Susceptibility is primarily genetic and appears to be due to the presence of a single autosomal gene. Females show a higher and earlier incidence of the commonest lethal manifestation, amyloid nephritis. To us the most striking resemblance to the human picture has been the relatively wide range of other autoimmune conditions that are associated with what we have taken as the central process of haemolytic anemia with positive direct Coombs test.
It should be evident that a great deal more work is called for with these animals. One might almost say that there is need to repeat all the immunological, pathological and therapeutic studies that have been made on human autoimmune disease with NZB/Bl mice and almost equally all the immunological and genetic work that has been done on normal mice. I have no doubt that if they are looked for other mutants of the NZB/Bl character will be found. What would be of special value would be to obtain a pair of co-isogenic strains differing only at the single genetic locus which is apparently involved.
The presence of immunological type lymphocytic proliferation in the thymus is perhaps the most significant of all the findings I have mentioned.
The close resemblance between the thymic lesions in myasthenia gravis and in the NZB/B1 mice immediately provokes a series of questions and hypotheses. Is the thymic lesion characteristic of some or all other autoimmune diseases? We must remember that for almost adventitious reasons myasthenia gravis is the only autoimmune disease in which the thymus is available for section except after death from a long illness. I know of nothing against the hypothesis that the thymus in an early case of SLE would show the same histological appearance as we find in myasthenia gravis and the NZB/B1 mice. If for the present we confine ourselves to these two conditions,-we must next ask whether the germinal centres and other signs of immunological activity in the thymus represent activity at the site of initiation of the disease process or are a secondary metastatic result of a process initiated elsewhere. I believe that within a year we should be able to provide the answer for the murine condition from a study of the time at which germinal centres are first found in the thymus in relation to the appearance of a positive D.C. reaction. A second line of approach which we are actively pursuing is to study mice of the back cross F1 x NZB/Bl for thymic lesions, to ascertain whether the appearance of a positive Coombs test and of thymic changes are genetically linked.
From the clinical angle I believe that much more interest must now be taken in the thymus in relation to autoimmune disease. With the techniques of thoracotomy now available, biopsy or total thymectomy should not offer an unreasonable hazard to selected patients with severe early autoimmune disease. Particularly in regard to systemic lupus erythematosus does it seem desirable to establish directly whether the thymus is involved in the initiation of the autoimmune process.
Conclusion I have stayed very much at the factual level in this talk and will try to round it off with only a brief summary of one theoretical interpretation of autoimmune disease which I believe is implicit in these results.
The evidence from the NZB/Bl mice is only of importance if they can legitimately be taken as a model of autoimmune disease in general and in particular if early thymic lesions are also present in other human autoimmune diseases than myasthenia gravis. It may turn out that the resemblance is purely coincidental but there is so much that is consistent with the new understanding of the thymus's role in immunity that I feel justified in stating our working hypothesis.
In summary, this is that the thymus is an organ sequestered from contact with foreign antigens, in which the process ofdifferentiation oflymphocytic cell lines for specific function takes place. It is also the site of the primary homeostatic process by which any cells which may have developed capacity to react with antigenic determinants present in accessible regions of the body can be destroyed or have their further development inhibited. We believe that the essential defect in the NZB/Bl mice (and in human autoimmune disease) is a genetically based lability as a result of which occasional lymphocytic stem cells develop a resistance to the normal intrathymic control. If these have the capacity to react with an antigen present in the thymus, and therefore by hypothesis an accessible self-component, both the appearance of germinal centres and plasma cells in the thymus and the development of autoimmune reactivity against one or more body antigens is to be expected. This is at present only a hypothesis but it is a hypothesis that calls for much specifically directed observational and experimental work both in human patients with autoimmune disease and in NZB/B1 mice or any other mammalian stocks with diseases of the same general quality that may be found. To that extent at least it is a good hypothesis.
